Clovis Oncology Inc (CLVS) 2016年年度报告「NASDAQ」.pdf

《Clovis Oncology Inc (CLVS) 2016年年度报告「NASDAQ」.pdf》由会员分享，可在线阅读，更多相关《Clovis Oncology Inc (CLVS) 2016年年度报告「NASDAQ」.pdf（113页珍藏版）》请在三个皮匠报告上搜索。

1、Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington,D.C.20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934.For the fiscal year ended December 31,2016.TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE

2、 ACT OF 1934.For the transition period from to .Commission file number:001-35347 Clovis Oncology,Inc.(Exact name of Registrant as specified in its charter)Delaware 90-0475355(State or other jurisdiction of incorporation or organization)(I.R.S.Employer Identification No.)5500 Flatiron Parkway,Suite 1

3、00 Boulder,Colorado 80301(Address of principal executive offices)(Zip Code)(303)625-5000 (Registrants telephone number,including area code)Securities registered pursuant to Section 12(b)of the Act:Title of each class Name of each exchange on which registered Common Stock par value$0.001 per share Th

4、e NASDAQ Global Select Market Securities registered pursuant to Section 12(g)of the Act:None Indicate by check mark if the registrant is a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes No Indicate by check mark if the registrant is not required to file reports pursuant

5、to Section 13 or Section 15(d)of the Act.Yes No Indicate by check mark whether the registrant(1)has filed all reports required to be filed by Section 13 or 15(d)of the Securities Exchange Act of 1934 during the preceding 12 months(or for such shorter period that the registrant was required to file s

6、uch reports),and(2)has been subject to such filing requirements for the past 90 days.Yes No Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site,if any,every Interactive Data File required to be submitted and posted pursuant to Rule 405 of R